John Hussman's PTCT Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 63.0K shares of PTC Therapeutics, Inc. (PTCT) worth $3.87 M, representing 0.84% of the portfolio. First purchased in 2018-Q2, this long-term strategic position has been held for 30 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 42.0K shares. Largest reduction occurred in Q4 2024, reducing 29.0K shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2018 | +50,000 | New Buy | 50,000 | $33.72 |
| Q3 2018 | -15,000 | Reduce 30.00% | 35,000 | $47.00 |
| Q4 2018 | +15,000 | Add 42.86% | 50,000 | $34.32 |
| Q2 2019 | -50,000 | Sold Out | 50,000 | $0.00 |
| Q4 2024 | +21,000 | New Buy | 21,000 | $45.14 |
| Q2 2025 | +42,000 | Add 200.00% | 63,000 | $48.84 |
John Hussman's PTC Therapeutics Investment FAQs
John Hussman first purchased PTC Therapeutics, Inc. (PTCT) in Q2 2018, acquiring 50,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held PTC Therapeutics, Inc. (PTCT) for 30 quarters since Q2 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q2 2018, adding 50,000 shares worth $1.69 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 63,000 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $3.87 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.84% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in PTC Therapeutics, Inc. (PTCT) was 63,000 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.